What is NCT04512345, and how is it related to Visipaque?
NCT04512345 is a ClinicalTrials.gov identifier for a specific clinical study. “Visipaque” is the brand name for iopamidol, an iodinated contrast agent used in imaging. To connect the trial to Visipaque, you’d typically look at the trial’s “Interventions” section on ClinicalTrials.gov to see whether iopamidol (Visipaque) is listed as the study product or comparator.
I don’t have the trial record content for NCT04512345 in the information provided here, so I can’t state which role Visipaque plays (main drug, comparator, dose/formulation, or imaging procedure) without checking the trial listing.
What should I look for in the trial record to confirm the Visipaque details?
If you open the ClinicalTrials.gov page for NCT04512345, the Visipaque-related answers are usually found under:
- “Interventions”: whether “iopamidol” / “Visipaque” appears by name, and the dosing/formulation.
- “Condition” and “Procedure”: what imaging is being done (for example, CT-related contexts).
- “Arms and Groups”: whether Visipaque is compared with another contrast agent or imaging strategy.
- “Primary outcome measures”: what the study is testing (often image quality, diagnostic performance, safety).
If you paste the “Interventions” text (or a screenshot) from the NCT04512345 page, I can translate it into a plain-English explanation of how Visipaque is being used.
Is Visipaque the same as iopamidol?
Yes. Visipaque is a brand of iopamidol, which is an iodinated contrast medium used to enhance visibility of structures during imaging. If a study lists iopamidol, it is the same active ingredient as Visipaque.
What are common concerns people have about iodinated contrast like Visipaque?
Searches around Visipaque often include safety topics. Typical points patients ask about include:
- Allergic reactions (especially prior contrast reactions).
- Kidney function considerations (risk of contrast-associated kidney issues in vulnerable patients).
- Thyroid effects in people with certain thyroid disorders (iodine load).
- Whether premedication is used for patients with prior contrast allergy.
To tailor this to NCT04512345, you’d need to see what the trial includes for inclusion/exclusion criteria and adverse-event monitoring.
How can you quickly verify the exact match between NCT04512345 and Visipaque?
The fastest way is:
1. Open the ClinicalTrials.gov record for NCT04512345.
2. Use the page search for “iopamidol” or “Visipaque.”
3. Confirm it appears under “Interventions” (not just in background text).
If you want, I can answer more precisely with one detail
Send either:
- the trial’s “Interventions” section text, or
- the Visipaque/iopamidol line(s) from the record,
and I’ll explain exactly what the study is doing with Visipaque (dose, comparator, purpose, and the outcome it’s measuring).
Sources
No sources were provided in your message, and I can’t access external pages from here to look up NCT04512345.